Our results indicate that a short period of 7 days under continuous treatment with 1,000 nM tamoxifen induces overexpression of GPER-1, making breast cancer cells more sensitive to tamoxifen, which following GPER-1 activation triggers DNA synthesis, an effect that can be blocked by a specific GPER-1 antagonist. This evidence concerns the gene GPER1 and breast cancer.